- Review
CPX-351 and the Frontier of Nanoparticle-Based Therapeutics in Acute Myeloid Leukemia
- Ioannis Konstantinidis,
- Sophia Tsokkou,
- Antonios Keramas,
- Eleni Gavriilaki,
- Georgios Delis and
- Theodora Papamitsou
Acute myeloid leukemia (AML) continues to carry a dismal prognosis in older adults and those with secondary or high-risk disease, where conventional 7 + 3 chemotherapy has long delivered complete remission rates below 40% and median overall survival...